Business Wire

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

− Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months − − At These Doses, Peak Reduction of Mean TTR ...
Business Wire

Alnylam Initiates Phase 3 Open Label Extension Study (“APOLLO-OLE”) with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of ...

CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated its Phase 3 open-label extension study ...